home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Events -> Courses and Workshops  

Monitoring Impurities in Pharmaceutical Products - ICH Q3 requirements

  August 29, 2013  
ComplianceOnline, Online Event

Why Should You Attend:

Monitoring impurities is considered a critical activity of analytical development in order to ensure the quality of the pharmaceutical products. Current ICH Guidelines indicate that the measurement of impurities should always be conducted for active pharmaceutical ingredient (API) and its drug products. This session will discuss the requirements of ICH Q3A/B for monitoring impurities in API and drug products, practical considerations when examine impurities, how they are reported in regulatory documentation, and key factors to consider when setting impurity specifications.

Learning Objectives:

Upon completion of this session, attendees will understand regulatory requirements in the monitoring of pharmaceutical impurities. Participants will gain practical knowledge about key considerations when reporting impurities for regulatory submission. This session will also discuss observations and infractions that were obtained due to recoding impurities in pharmaceutical labs.

Areas Covered in the Seminar:

  • Understand regulatory expectations.
  • Discuss warning letters and citations.
  • Understand regulatory requirement guidelines surrounding impurities in API and Drug Products.
  • Review ICH Q3A for controlling impurities in API and Q3B for impurities in Drug Products.
  • Understand different thresholds to report for regulatory submission.

Who Will Benefit:

To get the most out of the course, we highly recommended that you have at least two years of pharmaceutical analysis or drug development experience.
  • R&D analysts
  • QA and QC Managers
  • Regulatory scientists
  • Directors
  • Regulators and Researchers who are responsible for providing analytical data pertaining to pharmaceutical products
Organized by: ComplianceOnline
Invited Speakers: Kim Huynh-Ba, has almost 25 years of experience in analytical development, project management, strategic drug development and stability sciences. She is the Executive Director of Pharmalytik, where she provides consulting and training services to pharmaceutical companies including companies operating under FDA’s Consent Decree on harmonization and optimization of analytical best practices
Deadline for Abstracts: 2013-09-17
Registration: http://www.complianceonline.com/ecommerce/control/trainingFocus/~product_id=701781?channel=hummolgen
E-mail: referral@complianceonline.com
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.